DKSH, the leading Market Expansion Services provider with a focus on Asia, has been appointed by Sato Pharmaceutical, a well-known pharmaceutical company from Japan, to drive growth for the company's Hakubi and Tsuruko brands in China.
Media release
Shanghai, China, September 26, 2017 – DKSH Business Unit Healthcare, a leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia, and Sato Pharmaceutical have signed a strategic cooperation agreement for the Chinese market. A ceremony was conducted to mark the occasion, attended by senior executives from both parties.
Under the agreement, DKSH has been entrusted to provide marketing and sales, distribution and logistics services for its Hakubi, a fruit-flavor collagen drink, and Tsuruko, a non-stimulating skin care cream. Consumers in China will have access to the products across personal care stores, mom and baby stores, as well as through online channels. The collaboration is an extension of the partnerships with Sato Pharmaceutical and DKSH in Hong Kong, Malaysia and Taiwan.
“The goal of our company is to help people to lead healthier, happier lives. We are delighted to collaborate with DKSH, a trusted healthcare partner that has a deep understanding of the market and extensive market presence in the healthcare industry. With the help of DKSH, we continue to drive the development of our advanced, highly value-added products, and most importantly, our products are easily accessible to end-consumers,” said Seiichi Sato, President and CEO of Sato Pharmaceutical.
Teresa Chen, Regional Vice President, Healthcare, DKSH Greater China and Korea, added: “To work with Sato Pharmaceutical in China means we are building further strength for our local operation. We believe our professional market and sales performance with its wide coverage of retail and online channels will accomplish further promotion and popularization of the Sato pharmaceutical brand in China. We are proud to support Sato Pharmaceutical with its China expansion while helping more people in the country to get access to high-quality products.”
For further information please contact:
DKSH China Co., Ltd. | DKSH Management (Thailand) Limited |
Penny Gu Assistant Manager Branding and Communications Phone +86 21 5058 8241 penny.gu@dksh.com | Kalle Siebring Manager, Group Communications Business Unit Consumer Goods & Healthcare Phone +66 2 220 9739 kalle.siebring@dksh.com |
SATO Pharmaceutical Co., Ltd. Shanghai Office
KIN RI
Operation Director
18F Taiping Finance Tower, AD 488, Middle Yin Cheng Road, Pudong, Shanghai
Phone +86 21 6156 2309, Fax +86 21 6156 1619, Mobile +86 186 1653 1857
kin.ri@satopharm.com.cn
www.sato-seiyaku.co.jp, www.excellula.com.cn
About Sato Pharmaceutical
Following its founding in 1915, Sato Pharmaceutical’s main priority has been serving customer health by providing OTC products that are precisely designed to fit the real needs of the market. The company has kept this focus over the years by creating an ongoing series of top products as it continues to grow and succeed. Our goal is to help people to lead healthier, happier lives.
We want to be a force for helping people to achieve self-care, a desire backed by the technology, intelligence, and reliability that we have cultivated thus far. All of us at Sato Pharmaceutical continue to do everything we can to ensure the daily health of people around the world.
About DKSH
DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets. Publicly listed on the SIX Swiss Exchange since 2012, DKSH is a global company headquartered in Zurich. With 780 business locations in 36 countries – 750 of them in Asia – and 30,320 specialized staff, DKSH generated net sales of CHF 10.5 billion in 2016. DKSH was founded in 1865. With strong Swiss heritage, the company has a long tradition of doing business in and with Asia and is deeply rooted in communities and businesses across Asia Pacific.
DKSH Business Unit Healthcare is the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia. Custom-made offerings comprise registration, regulatory services, market entry studies, importation, customs clearance, marketing and sales, capillary physical distribution, invoicing and cash collection. Products available through DKSH Healthcare include pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With 120 business locations in 13 countries and around 9,740 specialized staff, Business Unit Healthcare serves over 150,000 customers and generated net sales of CHF 5.5 billion in 2016.